Cannabidiol Oral Solution ( DrugBank: Cannabidiol )

4 diseases

140. ドラベ症候群

臨床試験数 : 104 / 薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02318563 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solutionas an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Saf ...	Dravet Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	1 Year	30 Years	All	0	Phase 3	NULL

臨床試験数 : 101 / 薬物数 : 68 - (DrugBank : 12) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 60

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04133480 (ClinicalTrials.gov)	October 2020	17/10/2019	Investigation of Cognitive Outcomes With Cannabidiol Oral Solution	An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution(EPIDIOL ...	Lennox-Gastaut Syndrome	Drug: GWP42003-P	GW Research Ltd	NULL	Withdrawn	3 Years	10 Years	All	0	Phase 4	United States
2	NCT02318537 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solutionas an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safe ...	Lennox-Gastaut Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	2 Years	30 Years	All	0	Phase 3	NULL

臨床試験数 : 43 / 薬物数 : 54 - (DrugBank : 15) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 24

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03421496 (ClinicalTrials.gov)	September 5, 2018	26/1/2018	A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral SolutionWith Vigabatrin ...	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, ...	Infantile Spasm	Drug: Cannabidiol Oral Solution;Drug: Placebo;Drug: Vigabatrin	Benuvia Therapeutics Inc.	NULL	Terminated	1 Month	24 Months	All	2	Phase 3	United States

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05098509 (ClinicalTrials.gov)	March 15, 2022	22/9/2021	A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Wi ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution ...	Prader-Willi Syndrome	Drug: RAD011;Drug: Placebo	Radius Pharmaceuticals, Inc.	NULL	Not yet recruiting	8 Years	65 Years	All	220	Phase 2/Phase 3	United States
2	NCT03458416 (ClinicalTrials.gov)	September 6, 2018	2/3/2018	A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solutionin ...	A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Can ...	Prader-Willi Syndrome	Drug: Cannabidiol Oral Solution	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States
3	NCT02844933 (ClinicalTrials.gov)	June 6, 2018	22/7/2016	Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and To ...	Prader-Willi Syndrome	Drug: Cannabidiol;Drug: Placebo	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States